ann gidner Carl henric

SenzaGen recruits Dr. Carl-Henric Nilsson and Ann Gidner to the Board of Directors

-We are entering into a very exciting commercial phase and are happy to be able to engage board members with international experience from our target markets, says Prof. Carl Borrebaeck, chairman of the board of SenzaGen.

Carl-Henric Nilsson holds a PhD and M.Sc. in Industrial management, and is Associate Professor at Lund University, School of Economics and Management. He is CEO of Kunskapspartner AB, Chairman of Kunskapspartner Holding AB, Boardmember in FX International AB and Boffins Holding AB. Carl-Henric’s research is focused on Business development and Industrialization with numerous scientific publications. Carl-Henric is working with entrepreneurs on a global basis with a broad contact net, especially in China and the United States.

Ann Gidner holds a Master of Science in Chemical Engineering /Bioprocessing and a Bachelor in Business Administration. She has extensive international experience from the chemical industry with global leading positions in e.g. Cambrex and Lanxess Corporations. Furthermore, she has held managing positions in RFR Solutions AB, Semcon Caran AB, and Monocl AB. She is currently Director of Sales & Business Development Europe at Novozymes Biopharma, Copenhagen.

Other members of the board are chairman Carl Borrebaeck and deputy Malin Lindstedt.

For more information please contact:
Anki Malmborg Hager, CEO, SenzaGen AB
+46 768 284822

ceo senzagen anki malmborg hager

SenzaGen recruits Dr. Anki Malmborg Hager as CEO

We are very happy to have been able to recruit Dr. Malmborg, who has extensive experience from commercialization of academic results, financial markets and business developments says Prof.Carl Borrebaeck, chairman of the Board of SenzaGen.

Anki Malmborg Hager has more than 20 years´ experience in both pharmaceutical and biotech companies that are spin-offs from the University. She held the position as Investment Director in Lund University Bioscience AB between 2009 and 2011 as well as management positions in eg. Alligator Bioscience AB, XImmune AB (CEO), Cantargia AB (CEO), and Diaprost AB (CEO).

“I am very pleased to have been offered this opportunity” says Anki Malmborg Hager. “The underlying research in SenzaGen is world class and the market window of opportunity is timely and very exciting. I am looking forward to joining the SenzaGen team and to lead the next steps in the commercialization of many years of first-class research”.

For more information please contact:
Carl Borrebaeck, Chairman of the Board, SenzaGen AB
+46 708 218330